SG162616A1 - Combinations comprising epothilones and pharmaceutical uses thereof - Google Patents

Combinations comprising epothilones and pharmaceutical uses thereof

Info

Publication number
SG162616A1
SG162616A1 SG200608597-1A SG2006085971A SG162616A1 SG 162616 A1 SG162616 A1 SG 162616A1 SG 2006085971 A SG2006085971 A SG 2006085971A SG 162616 A1 SG162616 A1 SG 162616A1
Authority
SG
Singapore
Prior art keywords
combination
inhibitors
treatment
simultaneous
separate
Prior art date
Application number
SG200608597-1A
Other languages
English (en)
Inventor
John Arthur Hihneker
Julie Ann Miller
John David Rothermel
Markus Wartmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG162616A1 publication Critical patent/SG162616A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200608597-1A 2002-06-10 2003-06-06 Combinations comprising epothilones and pharmaceutical uses thereof SG162616A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38702502P 2002-06-10 2002-06-10
US40623902P 2002-08-27 2002-08-27
US40623802P 2002-08-27 2002-08-27
US43867703P 2003-01-08 2003-01-08
US43867603P 2003-01-08 2003-01-08

Publications (1)

Publication Number Publication Date
SG162616A1 true SG162616A1 (en) 2010-07-29

Family

ID=29741146

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200608597-1A SG162616A1 (en) 2002-06-10 2003-06-06 Combinations comprising epothilones and pharmaceutical uses thereof

Country Status (16)

Country Link
US (2) US20050271669A1 (https=)
EP (2) EP1515750B1 (https=)
JP (1) JP2005535608A (https=)
CN (2) CN101816792A (https=)
AT (1) ATE476995T1 (https=)
AU (1) AU2003242646A1 (https=)
BR (1) BR0311714A (https=)
CA (1) CA2487147A1 (https=)
DE (1) DE60333754D1 (https=)
IL (1) IL165180A0 (https=)
MX (1) MXPA04012444A (https=)
NO (1) NO20050096L (https=)
PL (1) PL372070A1 (https=)
SG (1) SG162616A1 (https=)
WO (1) WO2003103712A1 (https=)
ZA (1) ZA200409137B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
CN101677977A (zh) * 2006-11-10 2010-03-24 欣达克斯制药公司 用于治疗癌症的ERα+配体和组蛋白脱乙酰化酶抑制剂组合
WO2009015203A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
CA2725390C (en) * 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
WO2018081556A1 (en) * 2016-10-28 2018-05-03 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039694A2 (en) * 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
WO2000049019A2 (de) * 1999-02-18 2000-08-24 Schering Aktiengesellschaft Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US20020002162A1 (en) * 2000-03-27 2002-01-03 Lee Francis Y. Synergistic methods and compositions for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2322157C (en) * 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
HK1044946A1 (zh) * 1999-02-11 2002-11-08 舍林股份公司 依泊昔酮衍生物、其製備方法及藥物用途
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
JP2004500388A (ja) * 2000-03-01 2004-01-08 スローン−ケッタリング　インスティトュート　フォア　キャンサー　リサーチ エポチロン、その中間体およびその類似体の合成
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039694A2 (en) * 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
WO2000049019A2 (de) * 1999-02-18 2000-08-24 Schering Aktiengesellschaft Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US20020002162A1 (en) * 2000-03-27 2002-01-03 Lee Francis Y. Synergistic methods and compositions for treating cancer

Also Published As

Publication number Publication date
EP1515750B1 (en) 2010-08-11
ATE476995T1 (de) 2010-08-15
BR0311714A (pt) 2005-03-01
JP2005535608A (ja) 2005-11-24
MXPA04012444A (es) 2005-04-19
EP2179745A1 (en) 2010-04-28
CN101816792A (zh) 2010-09-01
NO20050096L (no) 2005-02-04
CA2487147A1 (en) 2003-12-18
IL165180A0 (en) 2005-12-18
AU2003242646A1 (en) 2003-12-22
WO2003103712A1 (en) 2003-12-18
EP1515750A1 (en) 2005-03-23
CN1658904A (zh) 2005-08-24
PL372070A1 (en) 2005-07-11
HK1075208A1 (en) 2005-12-09
US20050271669A1 (en) 2005-12-08
US20110033458A1 (en) 2011-02-10
DE60333754D1 (de) 2010-09-23
ZA200409137B (en) 2005-08-31

Similar Documents

Publication Publication Date Title
SG162616A1 (en) Combinations comprising epothilones and pharmaceutical uses thereof
WO2006059234A3 (en) Bicyclic amides as kinase inhibitors
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
IL284930A (en) History of pyrrolopyrimidines and their use in the treatment of protein kinase-related diseases
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
WO2004091591A3 (fr) Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives
MXPA04000567A (es) COMBINACIONES QUE COMPRENDEN EPOTILONAS Y SUS USOS FARMACeUTICOS.
SE0002729D0 (sv) Novel compound form
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2005074989A3 (en) Combination of a dna topoisomerase inhibitor and an iap inhibitor
PL377584A1 (pl) Deuterowane pochodne katecholoaminy oraz środki lecznicze zawierające te związki
TW200637542A (en) Lipase inhibitor, preventing and treating agent of skin disease
TW200628468A (en) Bicyclononene derivatives
TW200634002A (en) Chemical compounds
ECSP045479A (es) Combinaciones que comprenden epotilonas y sus usos farmaceuticos
HK1080369A1 (zh) 用於治疗多发性骨髓瘤的埃博霉素衍生物
MXPA04003124A (es) Composicion farmaceutica que comprende un agonista de adenosina a1/a2 y un inhibidor de intercambiadores sodio-hidrogeno.
RU2004139234A (ru) Комбинации, включающие эпотилоны, и их фармацевтическое применение
WO2004056306A3 (de) Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen
BR0312283A (pt) Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf
PL375503A1 (en) Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor
WO2004105738A3 (en) Use of tetrahydropyridine derivatives
EA200501366A1 (ru) Лекарственное средство